Survival of Patients with Malignant Pleural Effusion: A Single Center Study

Title Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Author Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif
Publication Date: 1401
Publication Place - Shiraz University of Medical Sciences, 1401.
Subject malignant, pleural effusion, survival, Medicine, Medicine (General), R5-920
Type Periodical
Language Persian
Digital Yes
Manuscript No
Physical Dimensions electronic resource
Library: Bursa Uludağ University Library
Library Asset ID edsdoj.74ee8bfe754a35aed51313fc821cc2
Record ID 7twhhxt6an
Library Location LCC:Medicine, LCC:Medicine (General)
Date 1401
Sample Text Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.
DOI 10.30476/smsj.2023.95854.1354
ISSN 2322-4339
İlişki https://smsj.sums.ac.ir/article_49095_e2e960cb6296ae59c5dc73bc242a35ae.pdf; https://doaj.org/toc/2322-4339
Bursa Uludağ University Library - Ottoman library catalog search Bursa Uludağ University Library

Survival of Patients with Malignant Pleural Effusion: A Single Center Study

Author Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif
Publication Date 1401
Publication Place - Shiraz University of Medical Sciences, 1401.
Subject malignant, pleural effusion, survival, Medicine, Medicine (General), R5-920
Type Periodical
Language Persian
Digital Yes
Manuscript No
Physical Dimensions electronic resource
Library Bursa Uludağ University Library
Library Asset ID edsdoj.74ee8bfe754a35aed51313fc821cc2
Record ID 7twhhxt6an
Library Location LCC:Medicine, LCC:Medicine (General)
Date 1401
Sample Text Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.
DOI 10.30476/smsj.2023.95854.1354
ISSN 2322-4339
İlişki https://smsj.sums.ac.ir/article_49095_e2e960cb6296ae59c5dc73bc242a35ae.pdf; https://doaj.org/toc/2322-4339
Bursa Uludağ University Library - Ottoman library catalog search
Bursa Uludağ University Library You are being redirected...

Please wait